Literature DB >> 17222753

Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule.

Timothy Madden1, Marcos de Lima, Neil Thapar, John Nguyen, Soonja Roberson, Daniel Couriel, Betty Pierre, Elizabeth J Shpall, Roy B Jones, Richard E Champlin, Borje S Andersson.   

Abstract

In pretransplantation therapy busulfan is typically given every 6 hours. We infused busulfan once daily at 130 mg/m2 for 4 days, performing pharmacokinetic analyses on plasma concentration-time data (n = 60 patients) on days 1, 3, and/or 4. Mean (percent coefficient of variation) maximum concentration, volume of distribution, half-life, and clearance were 3.6 microg/mL (13.8%), 22.6 L/m2 (20.2%), 2.73 hours (27.5%), and 109 mL/min/m2 (26%), respectively. The mean (percent coefficient of variation) and median daily areas under the curve were 4873 (21.8%) and 4871 microM x minute. Intrapatient variability in day-to-day estimated clearance was <20%, without day-to-day drug accumulation. The pharmokinetic parameters were compared with those from 47 patients given intravenous busulfan at approximately 0.8 mg/kg (approximately 32 mg/m2) every 6 hours. We conclude that there is (1) a dose proportionality based on mean and median areas under the curve, (2) unchanged estimated clearance with a 4-fold increase in dose and a 2.5-fold difference in dosing rate, (3) negligible variability in dose-to-dose pharmacokinetics and negligible interdose accumulation with once-daily administration, and (4) no change in pharmokinetic parameter(s) with concomitant use of imidazole antifungals, oral contraceptives, or phenytoin. In summary, intravenous busulfan has highly predictable, linear pharmacokinetics from 32 mg/m2 (approximately 0.8 mg/kg) to 130 mg/m2 (approximately 3.2 mg/kg). Further, once-daily intravenous busulfan dosing is convenient, favoring its more widespread application.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17222753     DOI: 10.1016/j.bbmt.2006.08.037

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  39 in total

1.  High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.

Authors:  Yago Nieto; Peter Thall; Ben Valdez; Borje Andersson; Uday Popat; Paolo Anderlini; Elizabeth J Shpall; Roland Bassett; Amin Alousi; Chitra Hosing; Partow Kebriaei; Muzaffar Qazilbash; Erin Frazier; Alison Gulbis; Christina Chancoco; Qaiser Bashir; Stefan Ciurea; Issa Khouri; Simrit Parmar; Nina Shah; Laura Worth; Gabriela Rondon; Richard Champlin; Roy B Jones
Journal:  Biol Blood Marrow Transplant       Date:  2012-05-27       Impact factor: 5.742

2.  Porous metal-organic-framework nanoscale carriers as a potential platform for drug delivery and imaging.

Authors:  Patricia Horcajada; Tamim Chalati; Christian Serre; Brigitte Gillet; Catherine Sebrie; Tarek Baati; Jarrod F Eubank; Daniela Heurtaux; Pascal Clayette; Christine Kreuz; Jong-San Chang; Young Kyu Hwang; Veronique Marsaud; Phuong-Nhi Bories; Luc Cynober; Sophie Gil; Gérard Férey; Patrick Couvreur; Ruxandra Gref
Journal:  Nat Mater       Date:  2009-12-13       Impact factor: 43.841

3.  Modelling of neutrophil dynamics in children receiving busulfan or treosulfan for haematopoietic stem cell transplant conditioning.

Authors:  Belén P Solans; Robert Chiesa; Bilyana Doncheva; Helen Prunty; Paul Veys; Iñaki F Trocóniz; Joseph F Standing
Journal:  Br J Clin Pharmacol       Date:  2020-03-03       Impact factor: 4.335

4.  Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.

Authors:  Partow Kebriaei; Roland Bassett; Genevieve Lyons; Ben Valdez; Celina Ledesma; Gabriela Rondon; Betul Oran; Stefan Ciurea; Amin Alousi; Uday Popat; Krina Patel; Sairah Ahmed; Amanda Olson; Qaiser Bashir; Nina Shah; Roy Jones; David Marin; Katayoun Rezvani; Yago Nieto; Issa Khouri; Muzaffar Qazilbash; Chitra Hosing; Elizabeth Shpall; Richard E Champlin; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2016-11-02       Impact factor: 5.742

5.  Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.

Authors:  Partow Kebriaei; Timothy Madden; Reza Kazerooni; Xuemei Wang; Peter F Thall; Celina Ledesma; Yago Nieto; Elizabeth J Shpall; Chitra Hosing; Muzaffar Qazilbash; Uday Popat; Issa Khouri; Richard E Champlin; Roy B Jones; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2010-07-30       Impact factor: 5.742

6.  Matched related and unrelated donor hematopoietic stem cell transplantation for DOCK8 deficiency.

Authors:  Jennifer Cuellar-Rodriguez; Alexandra F Freeman; Jennifer Grossman; Helen Su; Mark Parta; Heardley Murdock; Nirali Shah; Catherine Bollard; Heidi H Kong; Niki Moutsopoulos; Kelly Stone; Juan Gea-Banacloche; Steven M Holland; Dennis D Hickstein
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-27       Impact factor: 5.742

7.  Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients.

Authors:  Rosa F Yeh; Matthew A Pawlikowski; David K Blough; George B McDonald; Paul V O'Donnell; Andrew Rezvani; H Joachim Deeg; Jeannine S McCune
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-04       Impact factor: 5.742

8.  Intravenous busulfan: a guide to its use as conditioning treatment before transplantation of haematopoietic progenitor cells.

Authors:  Lesley J Scott; Sheridan M Hoy; Katherine A Lyseng-Williamson
Journal:  Clin Drug Investig       Date:  2012-09-01       Impact factor: 2.859

9.  Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.

Authors:  Jeannine S McCune; Meagan J Bemer; Jeffrey S Barrett; K Scott Baker; Alan S Gamis; Nicholas H G Holford
Journal:  Clin Cancer Res       Date:  2013-11-11       Impact factor: 12.531

10.  Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS.

Authors:  J De La Serna; J Sanz; A Bermúdez; M Cabrero; D Serrano; C Vallejo; V Gómez; J M Moraleda; S G Perez; M D Caballero; E Conde; J J Lahuerta; G Sanz
Journal:  Bone Marrow Transplant       Date:  2016-03-07       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.